Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center)
Cited by 22
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k